RIGEL PHARMACEUTICALS INC RIGL
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
5/9
Piotroski F — financial health
0.31
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $294.3M | $367.0M | — | — | $391.5M |
| 2024 | $179.3M | $17.5M | — | — | $3.3M |
| 2023 | $116.9M | -$25.1M | — | — | -$28.6M |
| 2022 | $120.2M | -$58.6M | — | -$74.2M | -$13.6M |
| 2021 | $149.2M | -$17.9M | — | $5.3M | $30.4M |
| 2020 | $108.6M | -$29.7M | — | -$53.4M | $34.0M |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 0.31 (distress)
- Working capital / assets 0.274
- Retained earnings / assets -1.992
- EBIT / assets 0.244
- Equity / liabilities 3.206
Source: SEC EDGAR filings · CIK 0001034842 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.